We may see 15c today, that is just $100m market cap, or USD$69m....

We may see 15c today, that is just $100m market cap, or USD$69m.

Peer, Akili sold a right for Japan & Taiwan’s markets for USD$20m cash plus USD$105m milestone payments. Their ADHD app is not FDA approved yet.
Plus they raised USD$140m over last few years.

Akili raises $55M to bring video game ADHD treatment to market
by Nick Paul Taylor |
May 9, 2018 8:45am

Akili's video game (Akili)
ShareFacebookTwitterLinkedInEmailPrint
Akili Interactive has raised $55 million to bring its prescription video game treatment for ADHD to market. The Temasek-led series C round comes five months after Akili posted positive data from a pivotal clinical trial of its digital medicine.


The trial partly validated Akili’s belief it can improve outcomes in ADHD and other conditions through video games designed to act on neural systems. Participants randomized to play the therapeutic game, AKL-T01, for four weeks performed better on a score of attention than those who played a nontherapeutic control game.

Misses against secondary endpoints weakened the dataset somewhat, but Akili has still persuaded some notable investors to bankroll its plans. In addition to national wealth fund Temasek, Akili raised money from Baillie Gifford and the VC wings of Amgen and Merck KGaA.

Akili Interactive Labs has raised a total of $140.9M in funding over 4 rounds.


Still Uncertain for Akili to achieve FDA approval as their trial missed secondary endpoints last year.